Active	Status	Sponsor type	Region	Phase	Filter
10 Active 5 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Merrill, Joan T
NAIVE, NCT04726553: Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE	Recruiting	1	20	US	Anifrolumab, Medi 546, Standard of Care, azathioprine, methotrexate, mycophenolate mofetil, corticosteroids, antimalarials	Oklahoma Medical Research Foundation, NYU Langone Health, Yale University, Piedmont Heart Institute, Inc., Atlanta, GA, Columbia University	Systemic Lupus Erythematosus (SLE)	12/23	12/24
Usman, Sabeena
SIRIUS-SLE 2, NCT05624749 / 2022-002690-29: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus	Recruiting	3	280	Europe, US, RoW	ianalumab, VAY736, placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Systemic Lupus Erythematosus	01/27	01/29
Yadav, Sudeep
MINT, NCT05799755: Myositis Interstitial Lung Disease Nintedanib Trial	Active, not recruiting	4	70	US	Nintedanib, OFEV, Placebo, Standard of Care	Rohit Aggarwal, MD, Boehringer Ingelheim	Myositis Associated Interstitial Lund Disease (MA-ILD)	07/25	12/25
Sheetal, Desai
No trials found